ASCO 2015 Highlights

Combination of Ibrutinib and BCL-2 or Spleen Tyrosine Kinase Inhibitors in Ibrutinib-Resistant Diffuse Large B-Cell Lymphoma

ASH 2014 - Castleman's Disease, ASH Highlights

Conference Correspondent

Ibrutinib in Patients with Bortezomib-Refractory Mantle-Cell Lymphoma

ASH 2014 - Castleman's Disease, ASH Highlights

Conference Correspondent

Ibrutinib in Relapsed/Refractory Mantle-Cell Lymphoma: 2-Year Results of Safety and Durability of Response

ASH 2014 - Castleman's Disease, ASH Highlights

Conference Correspondent

The Role of Hepcidin in Multicentric Castleman Disease

ASH 2014 - Castleman's Disease, ASH Highlights

Conference Correspondent

Idiopathic Castleman Disease: Clinical Features and Therapeutic Options

ASH 2014 - Castleman's Disease, ASH Highlights

Conference Correspondent

Restoration of Health with Siltuximab in Multicentric Castleman Disease

ASH 2014 - Castleman's Disease, ASH Highlights

Conference Correspondent

Siltuximab Efficacy in Multicentric Castleman’s Disease Is Independent of Baseline Symptom Burden

ASH 2014 - Castleman's Disease, ASH Highlights

Conference Correspondent

Adding Rituximab to CHOP Improves Clinical Outcomes in Mantle-Cell Lymphoma

ASH 2014 - Castleman's Disease, ASH Highlights

Conference Correspondent

Long-Term Maintenance with Rituximab in Elderly Patients with Mantle-Cell Lymphoma

ASH 2014 - Castleman's Disease, ASH Highlights

Conference Correspondent

Antagonism of Immune Effector Function by Ibrutinib or Obinutuzumab versus Rituximab

ASH 2014 - Castleman's Disease, ASH Highlights

Conference Correspondent

Page 208 of 329